CA2449002C - Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin - Google Patents

Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin Download PDF

Info

Publication number
CA2449002C
CA2449002C CA2449002A CA2449002A CA2449002C CA 2449002 C CA2449002 C CA 2449002C CA 2449002 A CA2449002 A CA 2449002A CA 2449002 A CA2449002 A CA 2449002A CA 2449002 C CA2449002 C CA 2449002C
Authority
CA
Canada
Prior art keywords
lecithin
cefditoren pivoxil
formulation
additional component
emulsified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2449002A
Other languages
English (en)
French (fr)
Other versions
CA2449002A1 (en
Inventor
Rajneesh Taneja
Dale Brinker
Jacqueline Briskin
Dilip Vishwasrao
Roberto Aponte
Pramod Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceuticals USA Inc
Original Assignee
Takeda Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals North America Inc filed Critical Takeda Pharmaceuticals North America Inc
Publication of CA2449002A1 publication Critical patent/CA2449002A1/en
Application granted granted Critical
Publication of CA2449002C publication Critical patent/CA2449002C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2449002A 2001-05-29 2002-05-28 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin Expired - Fee Related CA2449002C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86735301A 2001-05-29 2001-05-29
US29414101P 2001-05-29 2001-05-29
US60/294,141 2001-05-29
US09/867,353 2001-05-29
PCT/US2002/016428 WO2002096354A2 (en) 2001-05-29 2002-05-28 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin

Publications (2)

Publication Number Publication Date
CA2449002A1 CA2449002A1 (en) 2002-12-05
CA2449002C true CA2449002C (en) 2011-08-16

Family

ID=26968357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2449002A Expired - Fee Related CA2449002C (en) 2001-05-29 2002-05-28 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin

Country Status (5)

Country Link
EP (1) EP1401402B1 (enExample)
JP (1) JP5051865B2 (enExample)
CA (1) CA2449002C (enExample)
MX (1) MXPA03010945A (enExample)
WO (1) WO2002096354A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500712C (en) * 2002-10-02 2011-08-09 Meiji Seika Kaisha, Ltd. Antibiotic pharmaceutical composition with improved oral absorbability
EP1858488B2 (en) 2005-03-14 2022-07-20 Wyeth LLC Tigecycline compositions and methods of preparation
EP1954253A4 (en) * 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
JP2007106684A (ja) * 2005-10-11 2007-04-26 Sawai Pharmaceutical Co Ltd 抗菌性医薬組成物
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
WO2010066593A1 (en) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Combined drug administration
CN103781478A (zh) * 2011-06-24 2014-05-07 艾森达制药有限公司 用以改善酯类前药吸收率的方法与改良的药学组合物
KR101561963B1 (ko) * 2013-05-23 2015-10-22 영진약품공업 주식회사 세프디토렌 피복실의 신규 결정 형태 및 이의 제조 방법
EP3244879A1 (en) * 2015-01-16 2017-11-22 Ögün, Yusuf Toktamis Cefditoren pivoxil compositions with improved stability and production methods thereof
CN110143957B (zh) * 2019-06-20 2020-12-25 重庆医药高等专科学校 头孢妥仑匹酯开环物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58487B1 (en) 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPS6216431A (ja) * 1985-07-15 1987-01-24 Nakanishi Michio 医薬組成物
JPS62205088A (ja) 1986-03-03 1987-09-09 Meiji Seika Kaisha Ltd 新規セフエム化合物
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
WO1990015609A1 (en) * 1989-06-15 1990-12-27 Med-Tal, Inc. Prevention and treatment of microbial infection by phosphoglycerides
JP2785981B2 (ja) 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5319116A (en) 1992-02-12 1994-06-07 Gary Viole Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤
AR004014A1 (es) 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
AU4892897A (en) 1996-09-17 1998-04-14 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.

Also Published As

Publication number Publication date
EP1401402B1 (en) 2016-09-07
MXPA03010945A (es) 2004-02-27
EP1401402A4 (en) 2006-12-06
WO2002096354A2 (en) 2002-12-05
JP2005515155A (ja) 2005-05-26
CA2449002A1 (en) 2002-12-05
WO2002096354A3 (en) 2003-03-20
JP5051865B2 (ja) 2012-10-17
EP1401402A2 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
US20030060451A1 (en) Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
US8343543B2 (en) Lipase inhibiting composition
KR102162901B1 (ko) 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
EP1401402B1 (en) Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
HK1049798A1 (en) Solid lipid formulations
KR20240135688A (ko) 리소포스파티딜콜린 조성물
AU2002257817A1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
US4814353A (en) Therapeutic and prophylactic agent for gastritis
JP5110460B2 (ja) アトピー性皮膚炎用外用剤及びその製造方法
KR101281108B1 (ko) 항염증 활성을 갖는 리소포스파티딜에탄올아민 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항염증 조성물
JPH0455167B2 (enExample)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831